FN2 Earnings Intelligence
Moderna, Inc. earnings overview
Latest Moderna, Inc. (MRNA) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Moderna, Inc.
The quarter provided support for Moderna's commercial and pipeline expansion thesis through a revenue beat, flu-vaccine progress, global approvals, and continued oncology development. The evidence is mixed: the norovirus interim result, litigation cash cost, regulatory uncertainty, COVID-demand risk, and manufacturing constraints temper the outlook.
Moderna, Inc.
Moderna's first quarter of FY2026 beat consensus on both revenue and EPS, with $389M in revenue (a 65% surprise) driven by international partnerships, particularly the UK. A $950M Arbutus litigation settlement inflated the reported net loss to $1.3B, but the underlying loss narrowed to $0.5B as cost discipline held. Management maintained its 2026 revenue growth target of up to 10%, with EU approvals for the flu-COVID combo vaccine and upcoming oncology readouts as the next catalysts. The stock's muted reaction (-1.5% abnormal) suggests investors are looking past the headline beat toward pipeline execution and regulatory milestones later in the year.
Moderna, Inc.
The current analysis strengthens the case for a more constructive trajectory: management raised its guidance sentiment, cited up to 10% 2026 revenue growth, reported strong MNEXT Spike share, and highlighted pipeline progress. The thesis remains conditional because flu-program regulatory uncertainty, clinical readout timing, competition and international execution could limit delivery.
Moderna, Inc.
The quarter supports a mixed view: cost discipline and mNEXSPIKE share gains strengthen the operating trajectory, but weaker COVID demand, the CMV setback and reliance on future approvals leave the broader growth case unproven.
Moderna, Inc.
The quarter supports a mixed view: portfolio expansion, flu efficacy data and cost discipline strengthen the longer-term pipeline and operating outlook, while lower guidance, seasonal COVID demand and regulatory dependence limit near-term visibility.
Moderna, Inc.
The quarter supports a mixed view: resilient COVID demand, pipeline progress, and cost controls provide support, but declining dose volumes, weak initial RSV sales, and regulatory and manufacturing execution risks limit confidence in near-term growth.
Moderna, Inc.
The supplied analysis supports a mixed thesis: Moderna is expanding its respiratory and broader pipeline and reducing operating costs, but weaker near-term COVID and RSV demand, competition, and a lower sales outlook constrain the commercial case.
Get the MRNA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.